Brief: Camurus' Oczyesa Receives Marketing Authorization In EU
01/07/2025 14:40
July 1 (Reuters) - Camurus AB CAMX.ST: OCZYESA® RECEIVES MARKETING AUTHORIZATION FOR TREATMENT OF ACROMEGALY IN EU Source text: ID:nWkrbQd6Sk Further company coverage: CAMX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat